Live tracker
GLP-1 News & Updates
Reviewed July 28, 2026. Every item below is dated and linked to a primary source.
Where GLP-1s stand as of July 28, 2026
- Rybelsus is retired as a US brand. Oral semaglutide for type 2 diabetes now sells as the Ozempic pill, and the strengths changed with it: 1.5, 4 and 9 mg replace the old 3, 7 and 14 mg.
- Two oral GLP-1s are FDA-approved for weight loss: the Wegovy pill (oral semaglutide, 25 mg) and Lilly’s Foundayo (orforglipron). Neither is an injection.
- Wegovy also holds an accelerated approval for noncirrhotic MASH with F2-F3 fibrosis — a liver indication, separate from weight management.
- Retatrutide is NOT approved. It is in Phase 3, with roughly 28% weight loss reported in trials, and cannot be legally prescribed or compounded.
- Generic liraglutide is on the market, but the FDA lists liraglutide injection as having limited availability from some manufacturers — check supply before switching to it.
- The FDA has proposed permanently ending mass GLP-1 compounding. The public-comment period closed on 29 June 2026 and a final rule is pending, so the compounded market is operating on borrowed time rather than settled law.
- ·PipelineNot yet approved
Retatrutide Phase 3 reads out 28% weight loss — but it is not approved yet
No — retatrutide is not FDA-approved as of June 2026. Lilly’s triple-agonist posted ~28% average weight loss in Phase 3 (TRIUMPH-1, 28.3% at 80 weeks, reported May 21, 2026), but no New Drug Application has been filed; submission is expected in Q4 2026 with approval likely in late 2027.
Retatrutide (GLP-1 / GIP / glucagon) shows the largest weight loss of any GLP-1-class agent in trials so far. Until it is approved and launched (realistically 2028), the available options remain semaglutide and tirzepatide products — anything sold as “retatrutide” today is not an FDA-approved medicine.
Today’s strongest approved option: tirzepatide - ·RegulatoryFDA approved
Novo retires the Rybelsus brand in the US — oral semaglutide is now the Ozempic pill
Novo Nordisk retired the Rybelsus brand in the United States and pharmacies began dispensing the replacement on May 4, 2026. Oral semaglutide for type 2 diabetes now sells as Ozempic tablets, and the strengths changed with the rename: 1.5 mg, 4 mg and 9 mg replace Rybelsus 3 mg, 7 mg and 14 mg, because the tablet was reformulated to absorb better. Rybelsus continues to be sold under that name outside the US.
This is a branding and formulation change, not a safety withdrawal — no recall was issued. FDA’s drug shortage database records the Rybelsus NDCs as "to be discontinued", posted June 4, 2026, noting the products are replaced by Ozempic tablets. Two practical consequences: the switch needs a NEW prescription because a pharmacy cannot substitute one for the other, and the prescribing information says not to move between the two tablet products during the first 30 days of treatment. Note the indication — Ozempic tablets are approved for type 2 diabetes; the oral semaglutide approved for weight loss is the separate Wegovy pill at 25 mg.
The Ozempic pill — doses, cost and switching - ·RegulatoryProposed rule
FDA moves to permanently end mass compounding of GLP-1s
On April 30, 2026 the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them. The public-comment period closed June 29, 2026; a final rule is pending.
Both shortages are long resolved (tirzepatide December 2024, semaglutide February 21, 2025), so the legal basis for large-scale compounding is closing. If finalized, compounded GLP-1 access narrows sharply — confirm any compounded plan’s status with the provider before committing.
Compounded semaglutide — current status & cost - ·FDA approvalFDA approved
FDA approves Foundayo (orforglipron) — daily oral GLP-1, no food/water timing
Yes — the FDA approved Eli Lilly’s Foundayo (orforglipron) on April 1, 2026 for adults with obesity or overweight with weight-related conditions. It is the first oral GLP-1 pill for weight loss with no food, water, or time-of-day restrictions.
A once-daily non-peptide pill that achieved ~12% average weight loss at the highest dose over 72 weeks. Available via LillyDirect and retail/telehealth: about $149/mo self-pay for the lowest dose, as low as $25/mo with commercial insurance and the savings card, and $50/mo for eligible Medicare Part D from July 1, 2026.
Compare oral vs injectable tirzepatide cost - ·FDA approvalFDA approved
FDA approves the Wegovy pill — first oral GLP-1 for weight loss
Yes — the FDA approved the Wegovy pill (oral semaglutide 25 mg, once daily) on December 22, 2025, the first oral GLP-1 approved for weight management. It launched in the U.S. in early January 2026.
In the OASIS 4 trial oral semaglutide 25 mg delivered 16.6% mean weight loss when taken as directed, and it is also approved to reduce major cardiovascular events. Novo Nordisk set self-pay pricing around $149/mo, with insured copays that can fall to ~$25. The pill requires a 30-minute wait before eating, drinking, or other medicines.
Estimate your Wegovy cost - ·FDA approvalFDA approved
Wegovy becomes the first GLP-1 approved for MASH liver disease
On August 15, 2025 the FDA granted Wegovy (semaglutide 2.4 mg) accelerated approval for adults with noncirrhotic MASH and moderate to advanced liver fibrosis, stages F2 to F3 — the first GLP-1 receptor agonist approved for a liver indication. Cirrhosis is explicitly outside the indication.
The evidence is Part 1 of the phase 3 ESSENCE trial, published in the New England Journal of Medicine: 1,197 adults with biopsy-confirmed MASH randomised two to one to weekly semaglutide or placebo, with the reported analysis covering the first 800 at week 72. Steatohepatitis resolved without worsening fibrosis in 62.9% versus 34.3% on placebo; fibrosis improved without worsening steatohepatitis in 36.8% versus 22.4%. Read the approval type carefully: accelerated approval accepts improved liver histology as reasonably likely to predict clinical benefit, and the confirmatory part of ESSENCE, measuring liver-related events over 240 weeks, is not expected until 2029.
What is approved for each metabolic-syndrome component - ·GenericsNow available
Generic liraglutide arrives — the first generic GLP-1 for weight loss
Generic liraglutide is now available: the FDA approved the first generic of Saxenda (weight management) in August 2025, after Teva’s authorized generic of Victoza (diabetes) in June 2024. It is the first generic GLP-1 to reach the U.S. market.
Brand Saxenda runs $1,300–$1,800/mo cash; at launch generic liraglutide was seen as low as ~$230/mo at some pharmacies, though a typical cash price through 2026 has settled nearer $469/mo. More manufacturers were cleared to enter after February 24, 2026, which should push prices down further. Liraglutide is a daily injection and less potent than semaglutide/tirzepatide — but it is now the cheapest brand-equivalent GLP-1 route.
Saxenda (liraglutide) — providers & cost
Common questions
Is there a Wegovy pill, and is it FDA-approved?
Yes. The FDA approved the Wegovy pill (oral semaglutide 25 mg, once daily) on December 22, 2025 — the first oral GLP-1 approved for weight management. It launched in early January 2026 at roughly $149/mo self-pay.
Is orforglipron (Foundayo) approved?
Yes. The FDA approved Eli Lilly’s Foundayo (orforglipron) on April 1, 2026 — the first oral GLP-1 weight-loss pill with no food, water, or time-of-day restrictions, with ~12% average weight loss in trials.
Is retatrutide FDA-approved?
No. As of June 2026 retatrutide is not approved and no application has been filed. Phase 3 showed ~28% weight loss; an FDA submission is expected in Q4 2026 and approval likely in late 2027.
Can I still get compounded semaglutide or tirzepatide?
For now, but access is narrowing. With both shortages resolved, the FDA proposed on April 30, 2026 to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list; the public-comment period closed June 29, 2026 and a final rule is pending. Confirm current status with any provider before committing.
Prices moved — here is what providers charge right now
SponsoredPartner offers appear first and are marked Sponsored; the editorial score itself is never influenced by what a provider pays. Cash-pay pricing changes faster than any news page can; check the current figure with the provider.
Advertising disclosure: we may earn a commission if you sign up through these links, at no extra cost to you — it never affects our rankings. How we make money
- Sesame Care· from $208/moTop ratedTelehealth · online visit
- SkinnyRx· from $199/moCompounded not offered in AL, LA, MS — check before startingTelehealth · online visitCompounded · not FDA-approved
- Enhance MD· price shown after their intakeNo lab work to startRestricted in AL, AR, GA, HI, LA, MS, MO, ND, SC, TN, WV — check before startingTelehealth · online visitCompounded · not FDA-approved
- HealthRX· from $165/moLowest starting priceon the 12-month plan, $1,188 billed upfrontTelehealth · online visitCompounded · not FDA-approved
Compare your options
Pick a medication to see providers, cost, and savings.
GLP1Zoom is an affiliate-only comparator. This page summarizes publicly-reported regulatory and market events with primary sources; it is not medical advice. Drug approvals, prices, and supply change quickly — always confirm current status with the manufacturer, the FDA, or your prescriber.